FDA approves Gilead's new daily HIV pill to simplify treatment

The US Food and Drug Administration has approved a new daily HIV pill developed by Gilead Sciences. The drug targets patients who are already doing well on a single-tablet regimen, including those taking Biktarvy, and wish to switch to an alternative treatment. The approval is aimed at simplifying HIV therapy for certain patient groups.